|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2005-12-1
|
|
pubmed:abstractText |
Targeted radiotherapy of the bone marrow using radiolabeled monoclonal antibodies is a therapeutic approach of considerable potential for the treatment of acute leukemia in addition to or as a substitute for total body irradiation. The data currently available, of about 300 patients, suggest that radioimmunotherapy (RIT) with beta-emitters in acute leukemia is feasible and safe using a variety of antibodies (anti-CD33, anti-CD45, anti-CD66) and radionuclides (131I, 90Y, 188Re). It appears to reduce the risk of relapse in high-risk acute myelogenous leukemia (AML) patients transplanted early in the course of their disease (<15% blasts) to 20-30%. Furthermore, it has shown the potential to safely intensify reduced-intensity conditioning regimens (nonrelapse mortality of 25% compared to relapse rate of 55% within 2 years). Significant improvements in the results of refractory patients will probably depend on the successful further development of RIT with alpha-emitters or the use of a cocktail of antibodies labeled with alpha- and beta-emitters, in a first dose escalation study of 213Bi-labeled anti-CD33 in refractory AML (partial) remission could be achieved in 5/18 patients. Randomized trials to evaluate the therapeutic efficacy of RIT in the context of stem cell transplantation have been initiated and the results are keenly anticipated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD45,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/CD33 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/CD66 antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Cell Adhesion Molecules,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoconjugates,
http://linkedlifedata.com/resource/pubmed/chemical/Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Rhenium,
http://linkedlifedata.com/resource/pubmed/chemical/Yttrium Radioisotopes
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
36
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1021-6
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16247432-Alpha Particles,
pubmed-meshheading:16247432-Antibodies, Monoclonal,
pubmed-meshheading:16247432-Antigens, CD,
pubmed-meshheading:16247432-Antigens, CD45,
pubmed-meshheading:16247432-Antigens, Differentiation, Myelomonocytic,
pubmed-meshheading:16247432-Beta Particles,
pubmed-meshheading:16247432-Cell Adhesion Molecules,
pubmed-meshheading:16247432-Clinical Trials as Topic,
pubmed-meshheading:16247432-Dose-Response Relationship, Radiation,
pubmed-meshheading:16247432-Humans,
pubmed-meshheading:16247432-Immunoconjugates,
pubmed-meshheading:16247432-Leukemia,
pubmed-meshheading:16247432-Quality Control,
pubmed-meshheading:16247432-Radioimmunotherapy,
pubmed-meshheading:16247432-Radioisotopes,
pubmed-meshheading:16247432-Radiometry,
pubmed-meshheading:16247432-Rhenium,
pubmed-meshheading:16247432-Stem Cell Transplantation,
pubmed-meshheading:16247432-Yttrium Radioisotopes
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Radioimmunoconjugates in acute leukemia treatment: the future is radiant.
|
|
pubmed:affiliation |
Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. joerg.kotzerke@mailbox.tu-dresden.de
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|
